Date: 2017-05-15
Type of information: Nomination
Compound: member of the board of directors
Company: Bioverativ (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 15, 2017, Bioverativ announced the appointment of Geno J. Germano, a global biopharmaceutical industry executive with more than three decades of experience, to the company’s board of directors. This appointment brings Bioverativ’s total number of directors to six, five of whom are independent.
- Mr. Germano most recently served as President of Intrexon, a leader in synthetic biology. He previously held the positions of Group President, Global Innovative Pharma Business, and President and General Manager, Specialty Care and Oncology at Pfizer. Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals, including President of Wyeth U.S., and Johnson & Johnson.
- Mr. Germano is a member of Group of Fifty (G50), an executive group that seeks to promote openness among business leaders and to create economic and social progress. He also serves on the Board of Directors of Sage Therapeutics, Inc. and is on the Advisory Board of the Healthcare Businesswomen’s Association. He previously served on the Board of the Biotechnology Innovation Organization, where he chaired the International Committee and was a member of the Executive Committee. He is a Trustee of the Albany College of Pharmacy, from which he earned his bachelor’s degree in Pharmacy.
Financial terms:
Latest news:
Is general: Yes
